GSK Receives $44.13 Consensus Price Target Amid Analyst Ratings

GSK PLC Sponsored ADR (NYSE:GSK) has been assigned an average price target of $44.13 by a group of eleven brokerages currently assessing the company, according to Marketbeat.com. Analysts have provided mixed evaluations of the stock, with three issuing a sell rating, six opting for a hold rating, and two recommending a buy.

The average twelve-month target price reflects the assessments of analysts who have commented on the stock in the past year. Morgan Stanley reaffirmed an “underweight” rating on GSK shares in a report dated January 14, 2024. Conversely, Jefferies Financial Group restated a “buy” rating on October 27, 2023, while HSBC reiterated a “reduce” rating on December 10, 2023. Other analysts, such as TD Cowen, maintained a “hold” rating in a recent note.

Dividend Increase and Insider Transactions

In addition to the stock assessments, GSK recently announced a quarterly dividend of $0.4856 per share, which is set to be paid on April 9, 2024. Shareholders of record on February 20, 2024 will receive this payment. This marks an increase from the previous quarterly dividend of $0.42, resulting in an annualized dividend of $1.94 and a yield of 3.3%. The company’s payout ratio stands at 45.95%.

In a notable insider transaction, GSK’s major shareholder acquired 1,470,000 shares of the company on December 11, 2023, at an average price of $19.00 per share. This transaction amounted to approximately $27,930,000 and increased the insider’s holdings to 18,245,691 shares, valued at nearly $346.67 million. This acquisition represents an 8.76% increase in their position.

Institutional Investor Activity

Recent activity among institutional investors indicates a dynamic shift in GSK’s shareholder base. Brighton Jones LLC initiated a new position in GSK valued at about $528,000 in the fourth quarter. AQR Capital Management LLC significantly increased its stake by 84.4% during the first quarter, now holding 40,239 shares worth $1.56 million after acquiring an additional 18,420 shares.

Additionally, Empowered Funds LLC raised its stake by 2.1%, bringing its total to 79,174 shares valued at $3.07 million, while Yousif Capital Management LLC increased its holdings by 7.9% to reach 25,681 shares valued at approximately $986,000. Finally, Cullen Frost Bankers Inc. raised its stake by 4.7%, owning 375,481 shares worth about $14.42 million.

Currently, institutional investors and hedge funds collectively hold 15.74% of GSK’s stock, indicating a robust interest in the company amid fluctuating market conditions.

Overview of GSK

GSK, or GlaxoSmithKline plc, is a multinational pharmaceutical and healthcare company headquartered in London. It was formed through the merger of Glaxo Wellcome and SmithKline Beecham in 2000. The company operates globally, focusing on the development, manufacturing, and commercialization of prescription medicines, vaccines, and specialty treatments. Over its long history, GSK has strategically reshaped its portfolio, concentrating on science-led pharmaceuticals and vaccines. Core activities include research and development across various therapeutic areas, commercial manufacturing, and global marketing efforts.